Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CMR Surgical kicks off Versius Plus robot’s US commercial launch
(2h)
Philips AI cath lab copilot nets FDA clearance
(4h)
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
(4h)
OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
(4h)
Wave crashes after obesity trial tracks 1% dip in body weight over 6 months
(5h)
Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA
(8h)
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
(9h)
FDA approves Denali's Hunter syndrome drug, breaking streak of rare disease rejections
(1d)
Scaling Radioligand Therapy: Expanding the Impact of Theranostics
(1d)
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
(1d)
Takeda targets $1.3B in cost savings in further restructuring
(1d)
Endogenex nets $50M to carry intestinal diabetes procedure to the FDA
(1d)
Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
(1d)
Sarepta's big bet on Arrowhead's siRNA assets yields early data
(1d)
Novo Nordisk prepares to go global as triple G prospect passes midphase diabetes test in China
(1d)
BrightGene’s oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
(1d)
Icon, Advarra partnership aims to optimize trials, expand access
(2d)
GE HealthCare claims photon-counting CT clearance from FDA
(2d)
Medtronic, Biotronik heart hardware make strides in conduction system pacing
(2d)
Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors
(2d)
BioPharma Dive
Merck’s deal for Terns sparks debate over a possible biotech bidding war
(2h)
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
(3h)
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
(4h)
Maze tumbles on positive data for kidney disease drug
(23h)
Beam posts positive data on base editing treatment for AATD
(1d)
Sarepta sees early success with RNAi drugs from Arrowhead
(1d)
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
(1d)
RA Capital targets China with latest SPAC deal
(2d)
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
(2d)
Immutrin raises $87M to advance drug for progressive heart disease
(2d)
Karyopharm myeloma drug yields mixed data in myelofibrosis trial
(2d)
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
(2d)
Apogee strengthens case for longer-lasting eczema drug
(3d)
Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
(3d)
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
(3d)
Risk, readiness and resilience
(3d)
Earendil Labs, an AI-powered drugmaker, hauls in $787M
(6d)
Roche stops work on experimental SMA drug
(6d)
Novartis pays $2B to land a startup’s breast cancer drug
(6d)
Rhythm obesity drug wins broader use from FDA
(6d)
Endpoints News
Biopharma industry pushes back on FDA's 'America First' user fee proposals
(1h)
Recordati says it's received a $12B+ takeover bid
(1h)
UCB picks Georgia for $2B biologics site; AbbVie exec visits China
(2h)
New tech, familiar problems
(2h)
Wave crashes on obesity disappointment
(3h)
Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program
(4h)
Limbic aims to show AI beats humans in delivering therapy
(4h)
Post-Hoc: It’s time to make ACIP serious again
(4h)
Oral peptides biotech Pinnacle Medicines gets $89M from US, China investors
(7h)
FDA gives Denali accelerated approval for rare disease drug
(23h)
More changes ahead for Takeda with new CEO set to take reins
(23h)
How Seaport is hedging against failure in Phase 2b depression study
(1d)
FDA approves Corcept's Lifyorli for ovarian cancer months early
(1d)
After tumultuous year, Sarepta plots rebound with early data on RNA therapies
(1d)
Beam looks to accelerated approval for AATD base editing after promising update
(1d)
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure
(1d)
Novo reports more triple-G data from China; Grifols plots IPO for biopharma unit
(1d)
Microneedle vaccine patch company raises $50M for pivot to GLP-1 delivery
(1d)
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
(1d)
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
(1d)
BioSpace
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
(4h)
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
(6h)
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod
(7h)
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
(7h)
Beyond Buzzwords in Longevity Investing
(10h)
Leadership, Not Managers, More Likely To Drive Employees Away, BioSpace Finds
(11h)
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
(14h)
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
(23h)
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
(23h)
Despite Novo's Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
(1d)
UCB Investing $2B To Build Manufacturing Facility in Georgia
(1d)
11 Companies Hiring Now in New York
(1d)
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
(1d)
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
(1d)
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
(1d)
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
(1d)
Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape
(1d)
Trace Unites ALS Teams Behind a Target That Could Broaden Treatment Access
(1d)
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
(2d)
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
(2d)
STAT News
Eli Lilly’s deal man, Allogene’s off-the-shelf CAR-T, and Merck’s Terns buy
(1h)
Denali Therapeutics, Corcept Therapeutics win FDA approvals
(2h)
Health influencers talk social media and mental health
(3h)
A surprise opening for health care reforms
(4h)
White House misses deadline to nominate new CDC director
(4h)
Data show people racing to chatbots for health advice
(5h)
We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
(5h)
Allogene’s off-the-shelf CAR-T is nearing an early but pivotal study readout
(8h)
Endometriosis is not just a gynecological disease
(10h)
The perimenopause movement sells women the lie that they are ruled by their hormones
(10h)
CDC leadership in limbo as Trump administration set to miss deadline to nominate director
(21h)
California considers seal of approval for foods that are not ultra-processed
(23h)
Bhattacharya addresses CDC director role, works to bolster staff morale in first all-hands meeting
(1d)
Heart failure is common. A quick MRI could improve diagnosis and guide treatment
(1d)
FDA approves Denali Therapeutics drug for Hunter syndrome
(1d)
A 2023 health AI bet that seems to be paying off
(1d)
Sarepta Therapeutics shares rise on early promise for rare disease drugs
(1d)
Eli Lilly and the ‘societal obligation’ of GLP-1s
(1d)
We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
(1d)
How to make emergency rooms safer for people with dementia
(1d)
BioPharma Trend
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(1h)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(21h)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(1d)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(2d)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(3d)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(3d)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(3d)
AI-Guided Brain Implant for Memory Loss Gets FDA Breakthrough Status
(1w)
Dyno Launches Open-Source Agentic Protein Design Suite at GTC 2026
(1w)
AlphaFold Database Now Includes Protein Pair Interactions
(1w)
Basecamp Launches Trillion Gene Atlas Targeting Over 100 Million Species for Better AI Training Data
(1w)
Xaira Therapeutics Launches X-Cell, Its First Virtual Cell Model
(1w)
Roche Launches its Own AI Factory for Drug Development
(1w)
Arctoris Opens Biophysics Centre To Target Data Bottleneck in AI Drug Design
(1w)
Macrocyclic Peptide Startup Unnatural Products Raises $45M Series B After $3.5B in Pharma Deals
(1w)
First Invasive BCI for Paralysis Cleared for Everyday Use in China
(2w)
Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery
(2w)
From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now
(2w)
DeepMind & MIT Alumni Raise $13.5M to Build «Generative Knowledge Discovery» AI
(2w)
Breakout Ventures Raises $114M for Neuroscience and AI-driven Startups
(2w)
Drug Channels
Reflections and Photos from the Drug Channels Leadership Forum 2026
(1d)
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(2d)
Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
(6d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies
(1w)
Reshaping Patient Affordability: The Power of Expertise and Agility
(2w)
PBM Industry Update 2026: Trends, Challenges, and What’s Ahead (NEW Live Video Webinar)
(2w)
Time to Evolve: Hubs Flex to New Demands
(3w)
Preorder Now: DCI’s 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(3w)
Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences
(4w)
Drug Channels News Roundup, February 2026: Mark Cuban on FTC-ESI, What Patients Really Want, QALYs vs. MFN, 340B’s Site of Care Shift, and New Faces at DCI
(1mo)
The State of Patient Access: What Industry Leaders Reveal in a New Survey About Hub Models, Technology, and the Road Ahead
(1mo)
Medicare Part D Pharmacy Networks in 2026: Supermarkets Dominate as Drugstores Stall and Independents Walk Away
(1mo)
The Key to a Better Patient Experience: Improved GTN
(1mo)
Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
(1mo)
In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
(1mo)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel
(1mo)
Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending
(1mo)
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(1mo)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(2mo)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(2mo)
European Biotechnology Magazine
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
(2h)
Immutrin secures £65m Series A for amyloid-removing heart therapy
(1d)
Organoids: new Roche research centre in Basel will focus on alternative model systems
(1d)
Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics
(2d)
Mitigating regulatory risk with holistic CMC strategies
(2d)
Dutch biotech Laigo Bio bags €17m in oversubscribed seed round
(3d)
Leadership change
(3d)
Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
(6d)
Is the Unified Patent Court affordable for small biotechs?
(1w)
Recap AI Circular Economy Conference 2026
(1w)
A special look at SLAS Europe Conference
(1w)
Stop pipetting and start coding?
(1w)
European Partnerships for Biotech
(1w)
Leading Science this Spring & Summer
(1w)
Swiss Roche builds its own AI factory with NVIDIA – with Genentech in California
(1w)
Research and Innovation as a Competitive Advantage – Legal framework for Life Sciences made in Europe
(1w)
16th Euro Biotech Guide 2026 out now!
(1w)
16th Euro Biotech Guide 2026 out now!
(1w)
New Euro Biotech Guide edition out now!
(1w)
Mestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinic
(1w)
Drug Hunter
February 2026 Patent Highlights
(3h)
ACS Spring 2026 First Time Disclosures
(20h)
TL1A Inhibition in IBD: Deamplifying Biology for Clinical Proof-of-Concept
(2d)
QPX7728
(3d)
Dose as the Ultimate MPO Endpoint
(5d)
imatinib
(6d)
Thermal Stability Assays as Tools to De-Risk Discovery
(1w)
valbenazine
(1w)
zalsupindole
(1w)
vipoglanstat (GS-248)
(1w)
Module 2 Quiz
(1w)
2025 Molecule of the Year Nominees
(2w)
Beyond the Pill: Why Nasal Delivery Offers Unique Opportunities
(2w)
remibrutinib
(2w)
NX-1607
(2w)
ORN0829
(2w)
Module 2, Section 3: Target Validation
(2w)
BTK Degraders Racing to Change B-Cell Malignancies
(3w)
pirtobrutinib
(3w)
2025 Non-US Novel Large Molecule Drug Approvals
(3w)
Labiotech.EU
GSK’s two-speed strategy: broad sourcing and selective bets
(1d)
Seven T cell engager companies you should know about
(2d)
The six biotech companies in Portugal you should know about in 2026
(3d)
After the drought, biotech IPO activity begins to pick up in 2026
(6d)
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
(6d)
Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
(1w)
Promising biotechs in Maryland right now
(1w)
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff?
(1w)
Six biotech companies advancing the next generation of prostate cancer therapies
(1w)
How colorectal cancer treatment is evolving in 2026
(2w)
How to optimize your biotech company for partnering, licensing, and business success
(2w)
Cell rejuvenation therapy to hit clinic
(2w)
Desert to discovery: five hot biotechs in Arizona
(2w)
Carbios under pressure: financing struggles, China expansion, and a growing legal dispute
(2w)
11 anti-aging startups on a mission to extend lives
(3w)
Reversing tumor immunosuppression with next-gen GPCR modulation
(3w)
The biggest biotech funding rounds in February 2026
(3w)
Top biotech deals in February 2026
(3w)
Nine companies advancing biotech in Philadelphia
(3w)
Pulmonary hypertension after Winrevair: where GSK’s $950M bet fits
(3w)
Bio IT World
The Value of Prediction, and Cost of Success, in Drug Hunting
(13h)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(1d)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(2d)
PerturbAI Launches with CRISPR Atlas
(5d)
piRNAs Emerge as a New Frontier in Longevity
(1w)
Open Source ‘Floats All Boats’ in AI-Driven Drug Discovery
(1w)
Ancient Mushroom, Modern Medicine: Paul Stamets Says Agarikon Mycelium May Be Key to Fighting Viral Pandemics
(2w)
Russia to Expand National Genetics Database to Ensure Treatment for Various Ethnic Groups
(2w)
How HPC Systems Are Making Things Easier
(2w)
Infant Microbiome Atlas Makes Case for Region-Specific Probiotics
(3w)
MIT Develops Biodegradable “Smart Pill” to Track Medication Adherence
(3w)
Lee Hood’s Persistent Plan to Reinvent Medicine From the Ground Up
(3w)
Illumina Acquires SomaLogic, Sanofi’s New CEO, Parse Bioscience’s New Product Line
(1mo)
Follow the Money: International Expansion for Cell Therapies, BPZE1 Pertussis Vaccine, Next-Gen AI De Novo Antibody Design
(1mo)
Predicting When Alzheimer’s Symptoms Will Emerge
(1mo)
Welcome to the Next Frontier in Drug Discovery: The Surfaceome
(1mo)
Deloitte Survey Reveals Sharp Divide for This Year’s Outlook
(1mo)
Red Light Therapy Shows Promise for Treating Brain Injuries
(1mo)
New AI Approach Weighs Data ‘Temperature’ to Improve Prediction Accuracy
(1mo)
Redefining Hypertension Treatment with Brain’s Control Circuit
(1mo)
GEN News
From Variability to Reliability: A New IgG4 Reference Standard for Consistent Characterization
(5h)
Georgia Chosen as the Location for UCB’s New U.S. Biologics Manufacturing Facility
(6h)
Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout
(22h)
Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
(22h)
Parasites Prompt Gut-Brain Communication to Trigger Appetite Loss
(22h)
Epigenetic Memory from Inflammation May Prime the Gut for Colon Cancer
(23h)
The Three Pillars of Successful AI Deployments
(1d)
Biopharma Benefitting from AI in Manufacturing
(1d)
Scout-Triggered Proteomics Sharpens HCP Control
(1d)
Rentschler Highlights Milford Site Progress and Growth
(1d)
Xaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
(1d)
Genomic Mapping of E. coli Capsules Identifies High-Risk Types for Vaccines
(1d)
Sanofi Steps Up Autoimmune Push with Up-to-$1.23B+ Kali Collaboration
(1d)
Immunotherapy for Solid Tumors Enhanced by Metabolite-Sensing Receptors
(2d)
Glioblastoma Growth Mechanism Identified, Pointing to Potential Therapeutic Targets
(2d)
Judge’s Halt on RFK Jr.’s Vaccine Changes Remains in Effect, At Least for Now
(2d)
Modified Lipid Nanoparticles Boost mRNA Vaccine Delivery to Lymph Nodes
(2d)
Synthetic DNA Manufacturing Hub Set Up in Boston by Artis BioSolutions
(2d)
HIV Remains Suppressed in Some Patients After Treatment Withdrawal
(2d)
Skin Regeneration Enabled by Embryonic Healing Mechanism in Mice
(3d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(5d)
Understanding High-Risk Essential Thrombocythemia
(5d)
Son’s Decision to Donate Gave His Father a Second Chance
(5d)
Functional Precision Medicine Advances Brain Tumor Care
(6d)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(6d)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(6d)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(6d)
How Honest Conversations Strengthened a Couple After Cancer
(6d)
Cardiac Health in Cancer Survivors: A Growing Need
(6d)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(7d)
Understanding Mental Health Referrals in Cancer Care
(7d)
Breast Cancer Early Detection: A Bold and Breastless Survival Story
(1w)
Talzenna Plus Xtandi Delays Prostate Cancer Progression
(1w)
Evolving Treatment Strategies Are Reshaping mCRPC Care
(1w)
Pimicotinib Shows Early, Strong Tumor Response in Tenosynovial Giant Cell Tumors
(1w)
Life After Liver Cancer: A Couple’s Journey of Recovery and Care
(1w)
Why This Breast Cancer Survivor Chose "Flatness" After Implants
(1w)
NCCN Guidelines Expand Options for Certain Bladder Cancer Patients
(1w)
FOURLIGHT-1 Study Data Support Atirmociclib for HR+/HER2- Breast Cancer
(1w)
Key Updates in Bladder, Kidney and Prostate Cancer from Experts
(1w)
Contract Pharma
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery
(1h)
Lifecore Biomedical Inks Two New Agreements with Existing US Customer
(3h)
Piramal Pharma Solutions Procures Korsch X3 Tablet Press at Morpeth Facility
(22h)
Incyte Appoints Three to Executive Leadership Positions
(23h)
Sygnature Discovery Taps Susanne Back to Lead In Vivo Pharmacology Team
(1d)
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Registry
(1d)
UCB to Build New U.S. Biologics Manufacturing Facility in Georgia
(1d)
Axplora Accelerates Growth with HPAPI Investments
(2d)
Quotient Therapeutics, Merck Partner on IBD Drug Targets
(2d)
Rentschler Biopharma Advances Milford Site Expansion
(2d)
Artis BioSolutions Establishes Synthetic DNA Mfg. Hub in Boston
(2d)
ICON, Advarra Partner on Connected Site Network Model
(2d)
SwRI Opens New Clinical Supply Facility
(2d)
DCAT Member Company Announcement Forum 2026: An Inside Look
(2d)
Apollo to Acquire Minority Stake in Syntegon from CVC
(3d)
Kindeva Commemorates 70 years of the pMDI
(3d)
BARDA Contracts Just – Evotec Biologics to Optimize Biomanufacturing of Antibodies Against Filovirus
(3d)
Roche Inaugurates Research Facility for the Institute of Human Biology
(3d)
GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate
(3d)
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder
(3d)
Pharma Times
Laigo Bio completes final close of €17m seed financing round
(9h)
Axplora announces expansion as newest part of $60m API investment programme
(1d)
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
(2d)
Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
(3d)
Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
(1w)
Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
(1w)
Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
(1w)
Atrogi begins dosing first subjects in human trial of ATR-258
(1w)
R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
(1w)
Taiwan Bio partners with Terumo to advance automated Treg manufacturing
(1w)
Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
(1w)
Lebrikizumab shows strong results for children with atopic dermatitis
(1w)
MHRA approves new treatment for severe alopecia areata
(2w)
Aplagon doses first patient in phase 2a trial of APAC
(2w)
NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
(2w)
UCB reports superiority of bimekizumab in psoriatic arthritis study
(2w)
Kainova Therapeutics reports positive phase 1 results for DT‑9081 in advanced solid tumours
(2w)
EnteroBiotix completes enrolment for phase 2a trial of EBX‑102‑02 in stem cell transplant patients
(2w)
Lundbeck completes patient randomisation early in global MSA trial
(2w)
Incyte treatment for advanced anal cancer approved in Europe
(2w)
Medcity News
Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
(4h)
DPC Is Scaling — The Financing Architecture Isn’t Ready
(5h)
Personalized Rehab Solution: Supporting Patients With Work Responsibilities
(5h)
Could There Be a ‘Soft Opening’ of H.R. 1 Medicaid Changes?
(16h)
Adonis Scores $40M for AI Platform Aiming to Boost Hospital Revenue
(17h)
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
(1d)
A New Opportunity to Reduce Resident Burnout: Young Doctors Are AI Natives
(1d)
Key Amenity Categories in Luxury Rehabs, According to The Sanctuary at Sedona
(1d)
The FDA Is Fast-Tracking Health AI —Women’s Health Can’t Be Left Behind
(1d)
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
(1d)
How A Small Rural Hospital Is Using AI to Catch Heart Disease Sooner
(1d)
AHIP CEO: “We Are Laser-Focused on Affordability”
(1d)
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
(2d)
Virtual Specialty Care Has Time. Will We Use It Wisely?
(2d)
AI Won’t Replace Clinical Trial Teams, But It Fixes the Bottlenecks That Keep Patients Out
(2d)
Why Pure DTC Doesn’t Work in Healthcare, Per Muse Capital
(2d)
12 Senate Democrats Unveil Plan to Cut Costs, Expand Coverage
(2d)
Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products
(3d)
Imaging Interoperability Offers a Lifeline to Rural Hospitals and the Patients Depending on Them
(3d)
Why GI Providers Should Care About That “Health Hack”
(3d)
Chemical & Engineering News
Universities forge a bumpy new path on indirect research costs
(38m)
New drug candidates debut in Atlanta
(38m)
Supercapacitors built from bourbon waste
(3h)
Glyphosate could be boosting spread of multidrug-resistant bacteria
(5h)
How fish scales help reconstruct historical PFAS trends
(22h)
Surprisingly simple, sustainable lithium extraction
(23h)
Merck to buy Terns in $6.7 billion deal
(1d)
Progress toward a vaccine against oxycodone
(1d)
Editorial: The Iran war presents an energy reminder
(1d)
Lead-rich ash and dust traveled far afield of 2025 Los Angeles fires
(1d)
Women and early-career researchers hit hardest by NIH grant cancellations
(2d)
March 24 Business Watch: Helium capacity taken out in Qatar; Novartis to pay $2 billion for small molecule
(2d)
Antibiotics selectively supercharged against MRSA
(2d)
ACS offers new community service event at ACS Spring 2026
(2d)
Dino diets revealed by isotopes
(2d)
Comment: A future where the Women Chemists Committee is no longer necessary
(2d)
Chemists decipher cinchona alkaloid biosynthesis
(3d)
Protein-RNA cross-linking could make CRISPR more effective
(3d)
Memory Lane: ‘I don’t use computers’
(3d)
How do you study microplastics when they’re everywhere?
(3d)
The Pharma Letter
Wave hits the rocks on confounding obesity trial
(1h)
Second positive Phase III results for Kodiak’s Zenkuda
(2h)
Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape
(2h)
Global R&D Trends 2026
(3h)
BRIEF—Lonza launches new development lab in Singapore
(4h)
Norgine wins Swissmedic approval of Pedmarqsi
(4h)
FDA orders warning for Parkinson’s mainstay after seizure cases
(4h)
FDA wastes no time in approving Corcept’s Lifyorli
(4h)
FDA warning letter stands out for stark images of plant conditions
(5h)
GC Biopharma wins first LatAm nod for Barycela
(5h)
Early-stage data allows Sarepta to bounce back
(6h)
In Japan, high demand meets low price certainty
(6h)
Purple Biotech inks AI collaboration with Converge Bio
(7h)
Tempus, Daiichi team up on AI models for ADC development
(8h)
Mochida wins Japan approval for tocilizumab biosimilar
(8h)
Oryon Cell Therapies
(9h)
FDA approves drug to treat neurologic manifestations of Hunter syndrome
(10h)
Chugai wins Japanese regulatory approval for Lunsumio and Polivy combo
(1d)
Boehringer grows sales by 7.3% in a successful 2025
(1d)
Merck bids $6.7 billion for Terns Pharmaceuticals
(1d)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1w)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(1w)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(1w)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(1w)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(1w)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(1w)
PSMA PET Applications in Prostate Cancer Management
(1w)
FDA Confirms Potential Accelerated Path for Givastomig in GE Cancer
(1w)
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
(1w)
Deescalation Therapies in Breast Cancer Treatment
(1w)
Prospective Data Support i31-SLNB Test to Guide Biopsy Use in Melanoma
(1w)
LITESPARK-011 Signals Shifting Paradigm in RCC
(1w)
Biomarkers, Oncolytic Viruses, and the Promise of Personalized Treatment for Glioblastoma
(1w)
Priority Voucher Leads to Rapid Approval of Teclistamab in Myeloma
(1w)
How ctDNA Testing is Changing Lymphoma Treatment
(2w)
Symptom Burden, Functional Status, and Ongoing Challenges in Progressive Small Bowel Neuroendocrine Tumor
(2w)
MedWatch
Novo Nordisk chairman: Cost-cutting was the most challenging decision in 2025
(4h)
Gubra re-elects board of directors
(4h)
Lundbeck Foundation reshuffles its board of directors
(4h)
Sweden bans Novo Nordisk's advertising for Wegovy following criticism
(5h)
BioPorto remains committed to reducing its operating deficit
(6h)
Lene Skole resigns as Lundbeck Foundation CEO
(6h)
Ahead of Novo's annual general meeting: Shareholders hope for more clarity regarding Rebien's chairmanship
(9h)
Pharma giants cut over 22,000 jobs amid looming patent cliff
(10h)
BioPorto maintains full-year guidance
(10h)
Novo Nordisk makes another price cut to Wegovy in South Africa
(10h)
Novo Nordisk's type 2 diabetes data shows promise: Rival data expected later this year
(1d)
Novo Holdings increases its green share to 5.4% – but is slowing down in the new market climate
(1d)
MSD buys biotech Terns Pharmaceuticals for nearly USD 6bn
(1d)
Analyst: Novo Nordisk posts "remarkably strong" blood sugar results in new study
(1d)
MSD close to USD 6bn acquisition of Terns Pharmaceuticals
(1d)
Novo Nordisk reports promising phase 2 results for diabetes study
(1d)
Geopolitical turmoil wipes off USD 4bn from Demant owner's fortune
(2d)
Sonova aims to catch up in Asia with a new two-phase growth strategy
(2d)
Lundbeck CEO nominated to the board of Bavarian Nordic
(2d)
Valneva fails to meet primary endpoint in late-stage tick-borne virus vaccine trial
(2d)
In The Pipeline
Fentanyl's Membrane Behavior
(22h)
Set Phasers to "Kill". No, Not Those Phasers.
(1d)
AI-Predicting Compound Affinity. We Aren't There Yet.
(2d)
From Gut Bacteria Up to the Brain
(6d)
Beneficial Effects From the Liver to the Brain
(1w)
Now That's a Target-Guided Screen
(1w)
The Best Weapon Yet Against Sleeping Sickness
(1w)
Nitrogen, Ammonia, and the Strait of Hormuz
(2w)
In Cells and Outside of Them
(2w)
A Unique Situation for UniQure
(2w)
Dupeless Reeducation
(3w)
Dupeless Needication
(3w)
I Hadn't Bet On Diazos
(3w)
Hiding Way Down There
(3w)
Attitudes About Leaving Academia
(3w)
Feel the Antiviral Vibrations! Seriously.
(4w)
The Best Ideas Are Not Always Enough
(4w)
Affinity Above All?
(1mo)
An Early Cancer Detection Test, Put to the Test
(1mo)
The Adenovirus Vaccine Problems, Explained
(1mo)
Pharmaphorum
Wave's stock wavers on obesity drug data
(1h)
AI predicts liver cancer risk with "high accuracy"
(6h)
Corcept gets FDA OK for first-in-class ovarian cancer drug
(8h)
FDA clears Denali's 'game-changer' Hunter syndrome drug
(9h)
Anavex sinks after pulling Alzheimer's filing in EU
(23h)
ImmunityBio warned by FDA over 'misleading' Anktiva content
(1d)
Grifols board backs IPO for US business
(1d)
Patient sues Novartis, claiming data-tracking privacy breach
(1d)
Novo unveils first data for 'triple G' agonist in diabetes
(1d)
AI in drug discovery and development: news watch
(1d)
MSD rumoured to be nearing $6bn play for Terns Pharma
(1d)
Update: Rumour confirmed as MSD buys Terns for $6.7bn
(1d)
Karyopharm eyes Xpovio filing in myelofibrosis on mixed data
(2d)
MSD taps Quotient for IBD drug targets in $2.2bn deal
(2d)
AstraZeneca reportedly hit by serious cyberattack
(2d)
Keytruda cleared for NHS use in early head and neck cancer
(2d)
Gilead buys autoimmune disease biotech Ouro for $2.2bn
(2d)
Sanofi pays $180m for rights to Kali autoimmune drug
(3d)
Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss
(3d)
FDA seeks input into 'opaque' priority voucher scheme
(3d)
Drug Discovery Weekly
Global collaboration aims to create safer cancer therapeutics
(4h)
DDW Highlights: 26 March 2026
(7h)
Obesity could be treated without suppressing appetite
(8h)
Whitepaper: Secure your place in the IND race
(9h)
Just – Evotec Biologics enters $10m agreement with BARDA
(9h)
New protein drugs could pave way for faster drug development
(1d)
Gilead to advance first T cell engager for autoimmune diseases
(1d)
‘Supercharged’ T cells could improve prostate cancer treatment
(1d)
Twelve startups to showcase at SLAS Europe 2026
(1d)
Lilly’s triple agonist significantly reduces A1C and weight
(1d)
Study supports Treg enhancement as dementia treatment
(1d)
The next generation of CAR-T cell therapies
(2d)
Research uncovers how prostate cancer cells resist treatment
(2d)
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
(2d)
Laigo Bio raises $17m to advance oncology pipeline
(2d)
NHS health data should be used for clinical trial recruitment, says ABPI
(2d)
Last chance to register: Understand LC-MS quantification strategies for proteins
(2d)
Roche leads AI drug discovery with new NVIDIA deal
(3d)
EMA launches tools to accelerate development of medicines
(3d)
Collaboration to advance precision oncology therapy
(3d)
HIT Consultant
Beyond the AI Arms Race: Why Collaborative Intelligence Is the Only Path Forward for Utilization Management
(1d)
The RCM Trap: Why Cityblock Health is Pivoting AI Investment Toward Medicaid Care
(1d)
The C-Suite Squeeze: Why Hospital IT Budgets Are Shrinking While AI Spending Soars
(2d)
Hopper OS Acquires Healthcare Informatics Company Efferent to Expand Cloud PACS and Interoperability
(2d)
TruBridge and Artesia General Hospital Integrate Microsoft Dragon Copilot into EHR
(2d)
Cerebral Acquires Cognitive Behavioral Therapy App Inflow to Expand ADHD Treatment
(2d)
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
(2d)
Zocdoc Report: 26% of Patients Now Use AI for Medical Advice, Creating a ‘Triangle of Care’
(2d)
Viz.ai and Alnylam Pharmaceuticals Partner to Launch AI Care Pathway for Cardiac Amyloidosis
(2d)
AI Didn’t Fix HCC Coding—It Made It Harder. This is How to Fix It
(2d)
Rock Health Survey: 32% of Consumers Now Use AI for Health Information
(3d)
Flourish Care Secures $5.7M to Scale Reimbursed Doula Network Nationwide
(3d)
Samsung Medison Unifies NeuroLogica and Boston Imaging to Form Samsung HME America
(3d)
GE HealthCare Secures FDA 510(k) Clearance for Photonova Spectra Photon-Counting CT
(3d)
Clarius Mobile Health Launches T-Mode Heart and Knee for AI-Powered Ultrasound Training
(3d)
PromptWell and Ellipsis Health Partner to Transform AI Patient Engagement
(3d)
How CMS Policy Just Shifted 30% of Shoulder Surgeries Out of the Hospital
(3d)
Elpida Launches AI-Powered Marketing Compliance Platform for Healthcare Brands
(3d)
Health Universe Secures $6M for Healthcare AI Agent Platform
(6d)
LinusBio Expands Its Laser-Powered Hair Test to Help Rule Out Autism in Older Children
(6d)
Insights: Pink Sheet
Quotable: Top Experts On Policy Hot Topics
(4h)
Iran War: Fuel Woes Exacerbate Fragility Of Europe’s Medicines Distribution System
(5h)
India Tightens Oversight Of GLP-1 Supply Chain Amid Concerns Of ‘On-Demand’ Availability
(10h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome, Evidence Of US FDA Flexibility
(19h)
US FDA Allergenics Staff Sees Single-Trial ‘Default’ As Helpful
(22h)
GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not
(1d)
Speak To Multiple Regulators, Orchard Advises, Drawing On US Lenmeldy Challenges
(1d)
Regulatory Departments Must Prepare For The Digital-First Era In Europe
(1d)
Neurology Treatments From Scholar Rock & Sanofi Among Drugs Up For EMA Oral Explanations
(1d)
Korean Ministries Collaborate To Foster Bioventures, Blockbusters
(1d)
Soon-Shiong’s Statements Overstated Efficacy Of Immunity Bio’s Anktiva, US FDA Says
(1d)
China’s Threat To US Rx Sector Unifying Capitol Hill
(2d)
US FDA Layoffs Did Not Curtail Some PDUFA Spending
(2d)
Amgen’s Lung Cancer Treatment And Two Orphans Among Drugs Awaiting EMA Verdict
(2d)
Back Up Big Statements & Use Diagrams: The Key To ATMP Regulatory Success
(2d)
Obesity Drugs: A Missed Opportunity In England For Outcomes And Spending?
(2d)
China’s Out-Licensing Of Innovative Assets Seen As ‘Rational’ Policy-Driven Choice
(2d)
US FDA Seeks Higher Quality Responses To Form 483 Inspection Findings
(2d)
GDUFA IV: Industry Questions Proposed Four-Month pOAI Goal Extension
(3d)
Ascent’s US Myrbetriq Challenge Fails, Court Upholds Astellas Mirabegron Patents
(3d)
BioXconomy
How the Digital Medicine Society is advancing clinical trials with digital innovation
(2h)
DiMe CEO on how digital medicine is set to redefine clinical trials
(2h)
Merck bolsters oncology portfolio with $6.7bn acquisition of Terns
(7h)
PhaseV debuts AI offering to automate clinical trials
(1d)
Pfizer’s trispecific antibody shows promise in treating eczema
(1d)
‘Expect the unexpected’: Navigating biotech M&A in an unpredictable climate
(1d)
SEC leaders prioritize reducing regulatory burdens, streamlining disclosure rules for companies
(1d)
Peptide conjugates loosen up antibody therapeutics for range of conditions
(2d)
UK government to examine how AI can optimize trials
(2d)
Gilead’s $2.2bn buy of Ouro Medicines includes Galapagos alliance
(2d)
New finance chiefs named this month
(2d)
Spring has sprung: Laigo Bio closes $19.7m financing round for dual-target therapeutics
(2d)
What does it take to be a CFO today?
(2d)
CFO leaders see AI as copilot, not replacement
(2d)
Rivia raises $15m to scale agentic AI platform for clinical trials, expand US presence
(3d)
Novartis bags Synnovation’s breast cancer-fighting PI3Kα inhibitor for $2bn
(3d)
Crossbow Therapeutics hits the target with $77m Series B funding
(3d)
FDA demands sham arm for life-prolonging Huntington’s gene therapy
(6d)
GTN, collaboration and patient support
(6d)
Collegium strengthens ADHD portfolio with $650m buy of AZSTARYS from Corium
(6d)
BioCentury
Science Spotlight: AI studies link preserved thymic function to longer life
(18h)
With $6.7B buy, Merck sees ‘best-in-class’ blockbuster in Terns’ CML therapy
(19h)
Denali approval revives surrogate-endpoint path in neuronal MPS
(19h)
MHRA’s Tallon on the tall order of boosting the U.K. as a destination for clinical trials
(20h)
AL-S Pharma tests how far SOD1 biology extends into sporadic ALS
(1d)
Gilead seeks to defend HIV, reset I&I and bolster oncology
(1d)
Gilead seeks to put Galapagos’ cash to work as it buys bispecifics developer Ouro
(1d)
Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
(2d)
Apogee makes long-interval dosing case in atopic dermatitis, Valneva falls on Lyme disease data, and more
(2d)
J&J’s posdinemab data sharpen questions around tau biomarkers in Alzheimer’s
(2d)
Sanofi taps Kali for rights to clinical trispecific for immunology: Deals Report
(3d)
Scott’s push to decouple China-U.S. cell therapy R&D could cost both sides
(3d)
CytomX, Alto raise cash to support clinical programs: Public Equity Report
(5d)
Synnovation shareholders reap windfall from $2B sale of PI3Kα program to Novartis
(6d)
Excalipoint: Bringing co-stimulation, masking and more to solid tumor T cell engagers
(6d)
Where AI is integrating into the biotech venture funnel
(6d)
Ultra-rare disease community holds mock funeral at FDA
(6d)
Arrowhead’s bid to become a large-cap biotech
(6d)
Recursion’s Khan: AI will be judged by the medicines it makes
(6d)
Misfolding company Congruence returns to the well for $39.5M round: Venture Report
(7d)
SCRIP
How The Kelun-Merck Pact Shaped Future Of China Dealmaking
(2h)
Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
(4h)
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
(7h)
Biogen Added To Alteogen’s Long List Of Partners
(14h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome
(21h)
US FDA Approves Corcept’s Lifyorli For A Broad Ovarian Cancer Population
(21h)
Merck’s Case For Terns: Blockbuster Potential For TERN-701, Room For More Deals
(21h)
Beam To Extend Current Trial For Pivotal BEAM-302 Development
(22h)
Spring In The Step Is Back For Neuroscience Biotechs
(1d)
Novo And United’s Triple-G Agonist Scores In Diabetes Study
(1d)
Boehringer Issues Warning To Innovation-Unfriendly Europe
(1d)
Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410
(1d)
Merck To Buy Terns For $6.7bn, Boosting Blood Cancer Portfolio Further
(1d)
Lupin CEO And MD On Best-In-Class Innovation, Top Spot Ambition And Father’s Legacy
(1d)
From Super Bowl to CGT Nerve Centre And Trial Timelines: How Big Pharma’s India GCCs Add Value
(1d)
Multiple Chinese HER2 ADCs Close In On Enhertu In Breast Cancer
(1d)
China Companies’ Out-Licensing Deals ‘Rational’ But Policy-Driven
(1d)
Finance Watch: AI-Enabled Earendil Raises $787m After Prior Deals With Sanofi
(1d)
Roivant Sets The Stage For Its Next Commercial Act
(2d)
Karyopharm Aims For Xpovio Myelofibrosis Approval Despite Endpoint Miss
(2d)